loading page

The long-lasting istaroxime metabolite PST3093 stimulates SERCA2a and reverses disease-induced changes in cardiac function
  • +10
  • Martina Arici,
  • Mara Ferrandi,
  • Shih-Che Hsu,
  • Eleonora Torre,
  • Paolo Barassi,
  • Andrea Luraghi,
  • Carlotta Ronchi,
  • Gwo-Jyh Chang,
  • Franchesco Peri,
  • Patrizia Ferrari,
  • Giuseppe Bianchi,
  • Marcella Rocchetti,
  • Antonio Zaza
Martina Arici
Universita degli Studi di Milano-Bicocca
Author Profile
Mara Ferrandi
Windtree Therapeutics Inc
Author Profile
Shih-Che Hsu
CVie Therapeutics Limited
Author Profile
Eleonora Torre
Universita degli Studi di Milano-Bicocca
Author Profile
Paolo Barassi
Windtree Therapeutics Inc
Author Profile
Andrea Luraghi
Universita degli Studi di Milano-Bicocca
Author Profile
Carlotta Ronchi
Universita degli Studi di Milano-Bicocca
Author Profile
Gwo-Jyh Chang
Chang Gung University Graduate Institute of Biomedical Sciences
Author Profile
Franchesco Peri
Universita degli Studi di Milano-Bicocca
Author Profile
Patrizia Ferrari
Windtree Therapeutics Inc
Author Profile
Giuseppe Bianchi
Windtree Therapeutics Inc
Author Profile
Marcella Rocchetti
Universita degli Studi di Milano-Bicocca
Author Profile
Antonio Zaza
Universita degli Studi di Milano-Bicocca

Corresponding Author:[email protected]

Author Profile

Abstract

Background and Purpose. Heart failure (HF) therapeutic toolkit would strongly benefit from the availability of ino-lusitropic agents with a favorable pharmacodynamics and safety profile. Istaroxime is an agent, combining Na+/K+ pump inhibition and SERCA2a stimulation, shown by phase 2 trials to be promising in the acute setting. As PST3093 is an istaroxime metabolite reaching plasma concentration and duration greater than those of istaroxime, its evaluation is indispensable to establish its contribution to the istaroxime clinical efficacy. Experimental Approach. We studied PST3093 for its effects on SERCA2a and Na+/K+ ATPase activities, Ca2+ dynamics in intact myocytes and hemodynamic effects in an in-vivo rat model of diabetic (streptozotocin (STZ)-induced) cardiomyopathy. Key Results. The results converge to identify PST3093 as a “selective” (i.e. devoid of Na+/K+ pump inhibition) SERCA2a activator, thus differentiating it from its parent compound istaroxime. In in-vivo echocardiographic assessment, PST3093 improved overall cardiac performance (stroke volume and cardiac output) without decreasing heart rate, thus reversing many of STZ-induced abnormalities. Modulation of both systolic and diastolic indexes contributed to the improvement. For i.v. administration, PST3093 toxicity was considerably lower than that of istaroxime and its evaluation against a panel of 50 targets commonly involved in cardiac and extracardiac side-effects, failed to reveal significant interactions. Conclusion and Implication. PST3093 is a “selective” SERCA2a activator, the prototype of a novel pharmacodynamic category with a potential in the ino-lusitropic approach to HF therapy that may contribute to the clinical efficacy of istaroxime infusion.